Insider Profile
Geyer, Paul
1
Companies Filed At
1
Open-Market Buys (2yr)
$162K
Buy Value (2yr, open-market)
Mar 18, 2026
Most Recent Trade
1
Credibility
Score
33%
Hit Rate
-9.1%
Avg 90d Return
-6.3%
Median 90d Return
3
Evaluated Trades
+18.4%
Best Trade
-39.3%
Worst Trade
Hit rate and returns are based on 3 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.
Cross-Company Track Record
THIN HISTORY
—
Hit Rate · 90d
-37.4%
Median Alpha · 90d
2
Closed Buys Evaluated
0%
Beat XIU
All-insider base rate: 59% hit rate  · +1.3% mean alpha (n=11504)
size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research 2 closed buys with individual return outcomes available on the Research plan.
Date Company Role Nature Dir. Shares Price Value Score
Mar 18, 2026 $EPRX
Eupraxia Pharmaceuticals
— Exercise Buy 48,725 $3.00 $146K 73
Mar 18, 2026 $EPRX
Eupraxia Pharmaceuticals
— Open Market Buy 15,000 $10.80 $162K 73
Mar 18, 2026 $EPRX
Eupraxia Pharmaceuticals
— Exercise Sell 48,725 $3.00 $146K 73
Mar 09, 2026 $EPRX
Eupraxia Pharmaceuticals
— Expiry Sell 12,500 $11.20 $140K 73
Dec 15, 2025 $EPRX
Eupraxia Pharmaceuticals
— Comp. Grant Buy 10,000 $8.63 $86K 73
Dec 15, 2025 $EPRX
Eupraxia Pharmaceuticals
— Comp. Grant Buy 10,000 $8.63 $86K 73
Mar 31, 2025 $EPRX
Eupraxia Pharmaceuticals
— Expiry Sell 25,000 $8.00 $200K 73
Mar 25, 2025 $EPRX
Eupraxia Pharmaceuticals
— Comp. Grant Buy 45,000 $5.14 $231K 73
May 13, 2024 $EPRX
Eupraxia Pharmaceuticals
— Comp. Grant Buy 45,000 $3.96 $178K 73
Jan 08, 2024 $EPRX
Eupraxia Pharmaceuticals
— Expiry Sell 31,877 $5.60 $179K 73
Aug 18, 2023 $EPRX
Eupraxia Pharmaceuticals
— Open Market Sell 3,600 $7.00 $25K 73
Mar 09, 2021 $EPRX
Eupraxia Pharmaceuticals
— Open Market Buy 25,000 $8.00 $200K 73
Mar 08, 2021 $EPRX
Eupraxia Pharmaceuticals
— Other Sell — — — 73
Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.